Modality
Multispecific
MOA
PRMT5i
Target
GPRC5D
Pathway
Sphingolipid
PompeParkinson's
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
~May 2019
→ ~Aug 2020
Phase 3
~Nov 2020
→ ~Feb 2022
NDA/BLA
May 2022
→ Nov 2030
NDA/BLACurrent
NCT06084571
2,684 pts·Pompe
2022-05→2030-11·Recruiting
2,684 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-11-084.6y awayPh3 Readout· Pompe
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2030-11-08 · 4.6y away
Pompe
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06084571 | NDA/BLA | Pompe | Recruiting | 2684 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C |